VanEck's concentrated 25-stock approach offers higher individual company exposure, while Invesco's broader 251-position ...

IHE delivered 53.2% returns over one year with lower volatility and a 0.37% expense ratio, while PBE's quantitative biotech ...

Biotech ETFs can help investors capitalize on health care innovation while avoiding the boom-or-bust nature of individual firms.

State Street SPDR S&P Biotech ETF (XBI) is upgraded to buy as bullish momentum and reasonable valuation converge amid ...

Virtus Biotech ETF (BBP) gets a buy rating: equal-weight, quarterly rebalanced exposure to FDA-approved biotechs, deal ...

Designed to provide broad exposure to the Health Care ETFs category of the market, the Invesco Biotechnology & Genome ETF (PBE) is a smart beta exchange traded fund launched on 06/23/2005. What Are ...

Amid the trying circumstances in the market right now, investors may be well served to target the best biotech ETFs to buy. Fundamentally, these exchange-traded funds benefit from permanent relevance.

The biotech industry has been a robust roller-coaster over the last half decade. The State Street SPDR S&P Biotech ETF (NYSE: XBI), which tracks the biotech portion of the S&P 500, started in January ...

The Invesco Pharmaceuticals ETF (NYSEMKT:PJP) offers concentrated exposure to established, profitable drugmakers with lower volatility, while the State Street SPDR S&P Biotech ETF (NYSEMKT:XBI) ...

Biotech stocks are having one of their best stretches in years. The iShares Biotechnology ETF IBB jumped nearly 5% Wednesday ...

The investment seeks is to achieve 3 times (300%) the income generated from selling options on the S&P Biotechnology Select Industry Index (the “underlying index”) by selling options on leveraged ...

This was a new position; the IBB stake now accounts for 8.7% of Florin Court Capital LLP’s 13F AUM Top five holdings after the filing: ICLN: $16.6 million (13.0% of AUM) IBB: $11.1 million (8.7% of ...